Abbott Hosts Conference Call for Third-Quarter Earnings

9/24/25 9:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ABT alert in real time by email

ABBOTT PARK, Ill., Sept. 24, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its third-quarter 2025 financial results on Wednesday, Oct. 15, before the market opens.

The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at https://www.abbott.com/investors.html. An archived edition of the call will be available later that day.

About Abbott:

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

View original content:https://www.prnewswire.com/news-releases/abbott-hosts-conference-call-for-third-quarter-earnings-302565369.html

SOURCE Abbott

Get the next $ABT alert in real time by email

Recent Analyst Ratings for

$ABT

Date	Price Target	Rating	Analyst
4/22/2026	$92.00	Outperform → Neutral	Daiwa Securities
10/10/2025	$145.00	Buy	The Benchmark Company
7/18/2025	$145.00	Hold → Buy	Jefferies
6/16/2025	$143.00	Market Perform	Leerink Partners
10/8/2024	$130.00	Outperform	Oppenheimer
9/19/2024	$131.00	Overweight	Piper Sandler
7/30/2024		Buy → Hold	Edward Jones
5/30/2024	$121.00	Buy	Goldman

More analyst ratings

Abbott Hosts Conference Call for Third-Quarter Earnings

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$ABT

Abbott Hosts Conference Call for Third-Quarter Earnings

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$ABT

$ABT
Press Releases

Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes

ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening

Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026

$ABT
SEC Filings

SEC Form SD filed by Abbott Laboratories

SEC Form SCHEDULE 13G filed by Abbott Laboratories

SEC Form 10-Q filed by Abbott Laboratories

$ABT
Insider Trading

SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K

Director Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)

New insider Conroy Kevin T claimed ownership of 131,451 units of Common shares without par value (SEC Form 3)

$ABT
Insider Purchases

Director Starks Daniel J bought $926,537 worth of Common shares without par value (10,000 units at $92.65) and was granted 2,286 units of Common shares without par value, increasing direct ownership by 0.18% to 6,751,103 units (SEC Form 4)

EVP AND CFO Boudreau Philip P bought $201,300 worth of Common shares without par value (2,200 units at $91.50) (SEC Form 4)

Director Starks Daniel J bought $1,087,331 worth of Common shares without par value (10,000 units at $108.73), increasing direct ownership by 0.15% to 6,738,817 units (SEC Form 4)

$ABT
Analyst Ratings

Abbott Labs downgraded by Daiwa Securities with a new price target

The Benchmark Company initiated coverage on Abbott Labs with a new price target

Abbott Labs upgraded by Jefferies with a new price target

$ABT
FDA approvals

October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

$ABT
Leadership Updates

Abbott HeartMates Community Delivers Holiday Cheer in Hallmark Channel's New Movie "The More the Merrier"

Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent

Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

$ABT
Financials

Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences

Abbott hosts conference call for first-quarter earnings

Abbott completes acquisition of Exact Sciences

$ABT
Large Ownership Changes

SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

Abbott Hosts Conference Call for Third-Quarter Earnings

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $ABT

Abbott Hosts Conference Call for Third-Quarter Earnings

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $ABT

$ABT Press Releases

Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes

ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening

Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026

$ABT SEC Filings

SEC Form SD filed by Abbott Laboratories

SEC Form SCHEDULE 13G filed by Abbott Laboratories

SEC Form 10-Q filed by Abbott Laboratories

$ABT Insider Trading

SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K

Director Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)

New insider Conroy Kevin T claimed ownership of 131,451 units of Common shares without par value (SEC Form 3)

$ABT Insider Purchases

Director Starks Daniel J bought $926,537 worth of Common shares without par value (10,000 units at $92.65) and was granted 2,286 units of Common shares without par value, increasing direct ownership by 0.18% to 6,751,103 units (SEC Form 4)

EVP AND CFO Boudreau Philip P bought $201,300 worth of Common shares without par value (2,200 units at $91.50) (SEC Form 4)

Director Starks Daniel J bought $1,087,331 worth of Common shares without par value (10,000 units at $108.73), increasing direct ownership by 0.15% to 6,738,817 units (SEC Form 4)

$ABT Analyst Ratings

Abbott Labs downgraded by Daiwa Securities with a new price target

The Benchmark Company initiated coverage on Abbott Labs with a new price target

Abbott Labs upgraded by Jefferies with a new price target

$ABT FDA approvals

October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

$ABT Leadership Updates

Abbott HeartMates Community Delivers Holiday Cheer in Hallmark Channel's New Movie "The More the Merrier"

Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent

Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

$ABT Financials

Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences

Abbott hosts conference call for first-quarter earnings

Abbott completes acquisition of Exact Sciences

$ABT Large Ownership Changes

SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

Recent Analyst Ratings for
$ABT

Recent Analyst Ratings for
$ABT

$ABT
Press Releases

$ABT
SEC Filings

$ABT
Insider Trading

$ABT
Insider Purchases

$ABT
Analyst Ratings

$ABT
FDA approvals

$ABT
Leadership Updates

$ABT
Financials

$ABT
Large Ownership Changes